Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rituximab + recombinant interleukin-12
- Development stage
- Phase 2
- Lead developer
- Biogen
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
A combination immunotherapy regimen consisting of the CD20-directed monoclonal antibody rituximab and recombinant human interleukin-12 (rhIL-12). Rituximab binds to the CD20 antigen on the surface of normal and malignant B-lymphocytes, mediating cell lysis through complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC). Recombinant IL-12 is a proinflammatory cytokine that stimulates the production of interferon-gamma (IFN-γ) and enhances the activation and cytotoxic activity of natural killer (NK) cells and T-cells. The rationale for the combination is that IL-12-mediated activation of NK cells can significantly augment rituximab-induced ADCC. This combination was evaluated in Phase II clinical trials conducted by the National Cancer Institute (NCI) for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma.
- Other names
- rhIL-12rhIL12rhIL 12rIL-12rIL12rIL 12recombinant human interleukin-12
02
Targets
CD20 (B-lymphocyte antigen CD20)IL-12R (Interleukin-12 receptor)
Beyond the preview
Go deeper on rituximab + recombinant interleukin-12.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rituximab + recombinant interleukin-12.